BioCryst Pharmaceuticals Inc. Announces 2024 Annual Meeting of Stockholders

TL;DR

<b>BioCryst Pharmaceuticals will hold its Annual Meeting of Stockholders on June 12, 2024, to elect directors, ratify auditors, and vote on executive compensation and stock incentive plans.</b>

AI Summary

BIOCRYST PHARMACEUTICALS INC (BCRX) filed a Proxy Statement (DEF 14A) with the SEC on April 25, 2024. The Annual Meeting of Stockholders for BioCryst Pharmaceuticals, Inc. will be held on June 12, 2024, at 10:00 a.m. EDT. The meeting will take place at the company's corporate headquarters in Durham, NC. Key agenda items include the election of three directors, ratification of Ernst & Young LLP as independent auditors for 2024, and an advisory vote on executive compensation. Stockholders will also vote on the approval of an amended and restated Stock Incentive Plan. The company is a Delaware corporation and its fiscal year ends on December 31.

Why It Matters

For investors and stakeholders tracking BIOCRYST PHARMACEUTICALS INC, this filing contains several important signals. This filing is a proxy statement, indicating that the company is seeking shareholder votes on critical governance matters, including director elections and executive compensation. The proposed amendment to the Stock Incentive Plan suggests the company is looking to incentivize future performance and retain talent through equity awards.

Risk Assessment

Risk Level: low — BIOCRYST PHARMACEUTICALS INC shows low risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational risks apparent.

Analyst Insight

Review the nominated directors and executive compensation proposals to inform voting decisions.

Key Numbers

• 2027 — Director Term End Year (Directors elected will serve until the 2027 annual meeting.)
• 2024 — Independent Auditor Year (Ernst & Young LLP is proposed as the independent registered public accountants for 2024.)

Key Players & Entities

• BIOCRYST PHARMACEUTICALS, INC. (company) — Registrant Name
• Ernst & Young LLP (company) — Independent registered public accountants
• June 12, 2024 (date) — Annual Meeting date
• Durham, North Carolina (location) — Company headquarters address
• Delaware (location) — State of incorporation

FAQ

Risk Factors

• Compliance with SEC Regulations [low — regulatory]: The company must comply with all SEC rules and regulations regarding proxy solicitations and annual meetings.
• Stock Incentive Plan Administration [low — operational]: The effective administration and approval of the Stock Incentive Plan are crucial for employee motivation and retention.

Industry Context

BioCryst Pharmaceuticals is a biotechnology company focused on developing and commercializing medicines.

Regulatory Implications

The filing adheres to the Securities Exchange Act of 1934, specifically Section 14(a) and Regulation 14A, governing proxy solicitations.

What Investors Should Do

1. Review the biographies and qualifications of the nominated directors.
2. Analyze the details of the proposed amended and restated Stock Incentive Plan.
3. Understand the implications of the advisory vote on executive compensation.

Key Dates

• 2024-06-12: Annual Meeting of Stockholders — Key date for voting on corporate matters.

Glossary

DEF 14A

Definitive Proxy Statement filed with the SEC. (This document provides detailed information for shareholders to make informed voting decisions.)

Stock Incentive Plan

A plan that provides employees with equity-based compensation. (Approval of this plan is a key agenda item, impacting future employee compensation and shareholder dilution.)

Year-Over-Year Comparison

This is a DEF 14A filing, which is a definitive proxy statement for an annual meeting, typically filed annually.

Filing Documents

• bcrx-20240425.htm (DEF 14A) — 1194KB
• bcrx-20240425_g1.jpg (GRAPHIC) — 22KB
• bcrx-20240425_g2.jpg (GRAPHIC) — 125KB
• bcrx-20240425_g3.jpg (GRAPHIC) — 107KB
• bcrx-20240425_g4.jpg (GRAPHIC) — 115KB
• bcrx-20240425_g5.jpg (GRAPHIC) — 126KB
• bcrx-20240425_g6.jpg (GRAPHIC) — 94KB
• 0001628280-24-018175.txt (&nbsp;) — 3268KB
• bcrx-20240425.xsd (EX-101.SCH) — 2KB
• bcrx-20240425_def.xml (EX-101.DEF) — 2KB
• bcrx-20240425_lab.xml (EX-101.LAB) — 3KB
• bcrx-20240425_pre.xml (EX-101.PRE) — 1KB
• bcrx-20240425_htm.xml (XML) — 97KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 36 202 3 SUMMARY COMPENSATION TABLE 36 GRANTS OF PLAN-BASED AWARDS IN 202 3 37 OUTSTANDING EQUITY AWARDS AT DECEMBER 31, 202 3 38 202 3 OPTION EXERCISES AND STOCK VESTED 39 POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE IN CONTROL 40 CEO PAY RATIO 43 PAY VERSUS PERFORMANCE 44 202 3 DIRECTOR COMPENSATION 48 AUDIT COMMITTEE REPORT 50

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 51 STOCKHOLDER PROPOSALS 53 NO INCORPORATION BY REFERENCE 53 OTHER MATTERS 53 GENERAL INFORMATION 53 ANNEX A A- 1 TABLE OF CONTENTS BIOCRYST PHARMACEUTICALS, INC. 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 PROXY STATEMENT General This Proxy Statement is furnished in connection with the solicitation of proxies by the Board of Directors (the "Board" or the "Board of Directors") of BioCryst Pharmaceuticals, Inc. ("BioCryst" or the "Company") for the Annual Meeting of Stockholders of the Company to be held at our corporate headquarters at 4505 Emperor Blvd., Suite 200, Durham, NC 27703 on Wednesday, June 12, 2024 at 10:00 a.m., Eastern Daylight Time, and at any adjournment thereof (the "Meeting"), and for the purposes set forth in the accompanying Notice of Annual Meeting of Stockholders. In this document, the words "BioCryst," the "Company," "we," "our," "ours," and "us" refer only to BioCryst Pharmaceuticals, Inc. and not to any other person or entity. We are taking advantage of Securities and Exchange Commission ("SEC") rules that allow us to deliver proxy materials to our stockholders via the Internet. Under these rules, we are sending our stockholders a one-page notice regarding the Internet availability of proxy materials instead of a full printed set of proxy materials. Our stockholders will not receive printed copies of the proxy materials unless specifically requested. Instead, the one-page notice that our stockholders receive will tell them how to access and review on the Internet all of the important information contained in the proxy materials. This notice also tells our stockholders how to submit their proxy card on the Internet and how to request to receive a printed copy of our proxy materials. We expect to provide notice and electronic delivery of this Proxy Statement to such stockholders on or about April 25, 2024. We reserve the right to implement

View Full Filing

View this DEF 14A filing on SEC EDGAR